KYMR Kymera Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KYMR

Price (delayed)

$115.47

Market cap

$9.6B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.25

Enterprise value

$9.55B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 35
Highlights
KYMR's revenue has soared by 135% YoY and by 104% from the previous quarter
KYMR's gross profit has surged by 135% year-on-year and by 104% since the previous quarter
Kymera Therapeutics's quick ratio has increased by 24% YoY but it has decreased by 4.1% QoQ
KYMR's net income is down by 9% year-on-year but it is up by 4.9% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of KYMR

KYMR stock price

How has the Kymera Therapeutics stock price performed over time
Intraday
-5.4%
1 week
-0.74%
1 month
-3.61%
1 year
126.99%
YTD
48.4%
QTD
0.7%

Financial performance

How have Kymera Therapeutics's revenue and profit performed over time
Revenue
$105M
Gross profit
$105M
Operating income
-$350.18M
Net income
-$299.6M
Gross margin
100%
Net margin
-285.3%
KYMR's revenue has soared by 135% YoY and by 104% from the previous quarter
KYMR's gross profit has surged by 135% year-on-year and by 104% since the previous quarter
KYMR's net margin has surged by 54% year-on-year and by 53% since the previous quarter
The operating margin has soared by 52% from the previous quarter and by 52% YoY

Price vs fundamentals

How does KYMR's price correlate with its fundamentals

Growth

What is Kymera Therapeutics's growth rate over time

Valuation

What is Kymera Therapeutics stock price valuation
P/E
N/A
P/B
6.29
P/S
107.97
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
90.95
The company's EPS rose by 9% QoQ and by 7% YoY
The stock's price to book (P/B) is 80% more than its 5-year quarterly average of 3.7 and 45% more than its last 4 quarters average of 4.6
The equity has soared by 55% YoY
KYMR's revenue has soared by 135% YoY and by 104% from the previous quarter
The price to sales (P/S) is 104% higher than the 5-year quarterly average of 55.9 but 16% lower than the last 4 quarters average of 136.4

Efficiency

How efficient is Kymera Therapeutics business performance
The company's return on sales has surged by 54% YoY and by 53% QoQ
The company's return on equity rose by 32% YoY and by 14% QoQ
The return on invested capital has grown by 31% year-on-year and by 18% since the previous quarter
KYMR's return on assets is up by 28% year-on-year and by 13% since the previous quarter

Dividends

What is KYMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KYMR.

Financial health

How did Kymera Therapeutics financials performed over time
The total assets has grown by 45% YoY
Kymera Therapeutics's quick ratio has increased by 24% YoY but it has decreased by 4.1% QoQ
KYMR's debt is 95% smaller than its equity
The equity has soared by 55% YoY
Kymera Therapeutics's debt to equity has decreased by 44% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.